Mumbai, December 3 (Udaipur Kiran): Sun Pharmaceutical Industries was trading at Rs 1,808.70 on the BSE, up by 10.65 points or 0.59 per cent from its previous closing of Rs 1,798.05.
The stock opened at Rs 1,802.95 and touched a high of Rs 1,815.95 and a low of Rs 1,784.00 during the session. So far, 42,515 shares have been traded on the counter.
The BSE Group ‘A’ stock, with a face value of Rs 1, has hit a 52-week high of Rs 1,910.00 on December 31, 2024, and a 52-week low of Rs 1,547.25 on September 26, 2025. The stock’s one-week high and low stood at Rs 1,843.95 and Rs 1,784.00 respectively. The company’s current market capitalisation is Rs 4,33,295.90 crore.
Promoters hold 54.48 per cent stake in the company, while institutional and non-institutional investors hold 36.78 per cent and 8.73 per cent respectively.
Sun Pharmaceutical Industries’ wholly-owned subsidiary, Sun Pharma Laboratories, has received approval from its Board of Directors for an investment of Rs 3,000 crore to set up a greenfield formulations manufacturing facility in Madhya Pradesh.
Earlier, the company had launched its global innovative drug ILUMYA (Tildrakizumab) in India for the treatment of moderate-to-severe plaque psoriasis.
Sun Pharmaceutical Industries is the world’s fourth-largest specialty generic pharmaceutical company and India’s largest pharmaceutical company.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.